Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. (STAR-V)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05024695 |
Recruitment Status :
Recruiting
First Posted : August 27, 2021
Last Update Posted : August 27, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Glaucoma | Device: MINIject™ Implant | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 975 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space. The MINIject™ SO627 implant is manufactured from proprietary STAR® silicone material. |
Masking: | None (Open Label) |
Masking Description: | Person(s) checking intraocular pressures are masked, except for day of surgery, throughout the duration of the trial. |
Primary Purpose: | Treatment |
Official Title: | A Prospective, Multicenter Masked Clinical Trial to Evaluate the Safety and Effectiveness of the MINIject CS627 Implant in Subjects With Open Angle Glaucoma |
Actual Study Start Date : | August 19, 2021 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Implant Group |
Device: MINIject™ Implant
The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space. |
- Intraocular pressure decrease [ Time Frame: 24 months ]Proportion of subjects with ≥ 20% decrease (responders) from Baseline in unmedicated DIOP at Month 24.
- Intraocular pressure decrease (outcome 2) [ Time Frame: 24 months ]Change from baseline in mean unmedicated diurnal IOP at Month 24.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 46 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Males and females, 46 years of age or older
- A diagnosis of primary open-angle glaucoma, who are candidates for medical therapy, laser treatment, or glaucoma-filtering surgery
- Pseudophakic with prior uncomplicated cataract surgery
Key Exclusion Criteria:
- Angle closure, congenital, or secondary glaucoma
- Diagnosed degenerative visual disorders
- Clinically significant intraocular inflammation or infection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05024695
Contact: Abhi Vilupuru, Ph.D | 714-914-5527 | abhi.vilupuru@istarmed.us |
United States, Arkansas | |
Vold Vision | Recruiting |
Fayetteville, Arkansas, United States, 72704 | |
Contact: Steve Vold | |
Principal Investigator: Steve Vold, M.D. |
Study Chair: | Abhi Vilupuru, Ph.D | iSTAR Medical |
Responsible Party: | iSTAR Medical |
ClinicalTrials.gov Identifier: | NCT05024695 |
Other Study ID Numbers: |
ISM06 |
First Posted: | August 27, 2021 Key Record Dates |
Last Update Posted: | August 27, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
glaucoma MIGS primary open angle glaucoma suprachoroidal space supraciliary space |
Glaucoma Glaucoma, Open-Angle Ocular Hypertension Eye Diseases |